Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock

Published 17/08/2022, 23:33
Updated 18/08/2022, 00:10
© Reuters.  Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock

© Reuters. Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech Stock

Biotech stocks have the potential for huge gains if a product or drug is deemed effective and safe, but investing in the shares of those companies can be volatile.

Cathie Wood and her flagship ARK Innovation ETF (NYSE: ARKK) fund favored Crispr Therapeutics AG (NASDAQ: CRSP) in 2021, buying up millions of shares of the biotech company backed by Meta Platforms Inc (NASDAQ: META) CEO Mark Zuckerberg and Alphabet Inc (NASDAQ: NASDAQ:GOOGL)(NASDAQ: GOOG) co-founder Sergey Brin.

Though Wood has sold some of the position, Crispr is still the ninth heaviest stock in the ARKK portfolio, with around 5.7 million shares.

Read more: Analyst Sees 32% Upside On This Semiconductor Stock As Long As It Remains Above $62

Speculative investors and tech leaders aside, The Mercator analyst Gianni Di Poce sees 51% upside potential in the bio stock; here’s why.

The call: “I am bullish on CRSP so long as the stock remains above $69-$70,” Di Poce said. “Upside target $119-$121.”

The analyst penned in his weekly Benzinga Pro Insider Report that the company’s revenue soared to $914.9 million in 2021, up from just $719,000 in 2020. “With that growth trajectory,” he wrote, “valuation of the stock is not based on traditional fundamental metrics, but rather a belief in the story that gene editing will be a big part of our future.”

Check this out: 'The Bigger The Base, The Higher The Space': Analyst Sees 45% Upside Potential On This Mining Play'

Despite fundamental headwinds, the chart is showing a tight consolidation just under resistance of a rounding bottom pattern.

According to Emergen Research, the global gene editing market size was $5.2 billion in 2020 and is expected to reach $18.5 billion in 2028.

Crispr CEO Samarth Kulkarni said in the company’s Aug. 8 earnings call that the company remains in a strong position to bring transformative medicines for patients suffering from serious diseases.

“CRSPR has key drugs in its development pipeline, including one to treat sickle cells,” Di Poce said. “The stock is one FDA approval away from a burst higher in prices.”

Other analyst calls: Credit Suisse (SIX:CSGN) recently maintained its Neutral rating on Crispr, while RBC Capital maintained sector perform.

Photo: iQoncept via Shutterstock

Latest Ratings for CRSP

DateFirmActionFromTo
Feb 2022RBC CapitalMaintainsSector Perform
Feb 2022SVB LeerinkMaintainsOutperform
Dec 2021Cowen & Co.Initiates Coverage OnMarket Perform
View More Analyst Ratings for CRSP

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.